Brain Metastasis in Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations
- 1 September 2013
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (25) , 3162-3164
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastasesRadiation Oncology, 2012
- Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic featuresLung Cancer, 2012
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancerNeuro-Oncology, 2010
- Brain metastases from lung cancer responding to erlotinib: the importance ofEGFRmutationEuropean Respiratory Journal, 2010
- EGFR testing in lung cancer is ready for prime timeThe Lancet Oncology, 2009
- Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical ResponseClinical Cancer Research, 2008
- Frequent EGFR mutations in brain metastases of lung adenocarcinomaInternational Journal of Cancer, 2006
- Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung AdenocarcinomasJournal of Clinical Oncology, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004